Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262510 | 0.89 | CYP2D6 (0.72) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL20676125 | 0.87 | CYP2D6 (0.70) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL24565989 | 0.86 | ALDH1A1 (0.54) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL10104420 | 0.86 | ALDH1A1 (0.58) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL13960087 | 0.84 | ALDH1A1 (0.60) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL3971878 | 0.84 | CXCR4 (0.56) | MEN1KMT2ACXCR4SIGMAR1CHRM3 | |
| SCHEMBL19262611 | 0.83 | CYP3A4 (0.61) | CYP2D6CYP3A4TSHRMEN1TP53 | |
| SCHEMBL428016 | 0.83 | CHKA (0.52) | CYP2D6CYP3A4TSHRCYP2C19USP2 | |
| SCHEMBL12426565 | 0.83 | ALDH1A1 (0.51) | CYP2D6CYP3A4TSHRCYP2C19USP2 | |
| SCHEMBL21951132 | 0.82 | HIF1A (0.56) | CYP2D6CYP3A4TSHRCYP2C19USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CYP2D6 223/4885CYP3A4 249/4885TSHR 1311/4885 |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K3, MAP3K20 | CYP2D6 1808/4885CYP3A4 2653/4885TSHR 3586/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CYP2D6 223/4885CYP3A4 249/4885TSHR 1311/4885 |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | CYP2D6 1798/4885CYP3A4 2859/4885TSHR 3808/4885 |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | CYP2D6 1984/4885CYP3A4 3437/4885TSHR 3947/4885 |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | CYP2D6 31/4885CYP3A4 973/4885TSHR 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.